NCT07075289View on ClinicalTrials.gov

Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

August 31, 2024

Study Completion Date

December 27, 2024

Conditions
Benign Paroxysmal Positional Vertigo (Disorder)
Interventions
DRUG

DLBS1033

Participants would get oral lumbrokinase DLBS1033 (490 mg, DISOLF film-coated tablet, Dexa Medica b.i.d.) for a 14-day prospective observation period.

DRUG

Betahistine Mesylate tablet

Patients would get betahistine mesylate (12 mg, MERTIGO SR tablet, Dexa Medica b.i.d.) for a 14-day prospective observation period.

Trial Locations (1)

57126

Dr. Moewardi Regional General Hospital, Surakarta

Sponsors

Collaborators (1)

Dexa Medica Group
All Listed Sponsors
collaborator

Dexa Medica Group

INDUSTRY

lead

Universitas Sebelas Maret

OTHER

NCT07075289 - Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo | Biotech Hunter | Biotech Hunter